Latest News and Press Releases

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford,...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia Proof of Concept Now Established in Animal...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019 Oxford, UK, and Cambridge, MA, US,...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Result of Annual General Meeting Oxford, UK, and Cambridge, MA, US, 19 June 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM)...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract...

Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Oxford, UK,...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2019 Oxford, UK, and Cambridge, MA, US, 5 June 2019...

Summit Therapeutics plc  (‘Summit’ or the ‘Company’) Publication of UK Annual Report and Notice of Annual General Meeting Oxford, UK, and Cambridge, MA, US, 14 May 2019 - Summit Therapeutics plc...

BLOCK LISTING SIX MONTHLY RETURN  (Note: Italicised terms have the same meaning as given in the Listing Rules.) Date: 29 April 2019 Name of applicant:Summit Therapeutics plcName of scheme:2005 EMI...

Summit Therapeutics plc  (‘Summit’ or the ’Company’) Exercise of Restricted Stock Units and Total Voting Rights Oxford, UK, and Cambridge, MA, US, 24 April 2019 – Summit Therapeutics plc (NASDAQ:...